Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026
Vericel (NASDAQ:VCEL) will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vericel (NASDAQ:VCEL) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m. ET (11:15 a.m. PT).
A live webcast of the presentation will be available on the company’s Investor Relations website at http://investors.vcel.com.
Details
News Market Reaction – VCEL
On Jan 6, the day this news came out, VCEL closed 6.09% above the previous close.
Data tracked by StockTitan Argus for the Jan 6 session.
Key Figures
- Conference edition
- 44th Annual
- J.P. Morgan Healthcare Conference
- Presentation time ET
- 2:15 p.m. ET
- J.P. Morgan Healthcare Conference session
- Presentation time PT
- 11:15 a.m. PT
- J.P. Morgan Healthcare Conference session
- Presentation date
- January 14, 2026
- J.P. Morgan Healthcare Conference appearance
Historical Context
-
Announcement of participation in Stephens Annual Investment Conference via webcast.
-
Record Q3 2025 revenue, margin strength, and reaffirmed full‑year guidance.
-
Scheduling of Q3 2025 earnings call and webcast details for investors.
-
Notice of participation in Wells Fargo Healthcare Conference fireside chat.
-
Strong Q2 2025 revenue, margin expansion, and MACI growth but sharp selloff.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference at 2:15 p.m. ET (11:15 a.m. PT) on Wednesday, January 14, 2026.
A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Epicel® and MACI® and MACI Arthro® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. ©2026 Vericel Corporation. All rights reserved.
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.